Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVR-T3011 in BCG-failure NMIBC
NCT06427291Phase 1Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MVR-T3011 in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Fudan University. Primary endpoints: Complete Response Rate at 12 months, Recurrence-Free Survival at 2 years and 9 more. Started Sep 2023; status: recruiting.
02
Drugs
MVR-T3011
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06427291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06427291.